Nina Kjellson has been investing in health care at InterWest since 2002 and has been a Managing Director at the firm since 2008. Current investments include Alvine Pharmaceuticals, Alt12, Cebix, Cidara, Eiger Biopharmaceuticals, Lycera, Ocera (OCRX), and WellTok. Nina also co-sponsored InterWest's investment in TESARO (TSRO). Previous investments include Labrys Biologics (acquired by Teva), Trius Therapeutics (TSRX; acquired by Cubist), CNS Therapeutics (acquired by Covidien), NovaCardia (acquired by Merck), and Aspreva (ASPV; acquired by Galenica). Nina leads InterWest's cross-sector initiative in health care IT and is co-chair of the Consumer Medicine Summit, a forum for entrepreneurs at the intersection of health care and consumer innovation. She serves as a mentor to Nike+ and Blueprint Health accelerators. Prior to joining InterWest, Nina was at Bay City Capital, Oracle Partners and the Kaiser Family Foundation. She is a graduate of Stanford University with a degree in Human Biology.